Evidence map›Paper›PMID 27086924›Full record

ArticleOncogene2016

ERK1/2-induced phosphorylation of R-Ras GTPases stimulates their oncogenic potential.

C Frémin, J-P Guégan, C Plutoni, J Mahaffey, M R Philips, G Emery, S Meloche

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C FréminInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
J-P GuéganInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
C PlutoniInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
J MahaffeyDepartments of Medicine, Cell Biology and Pharmacology, Perlmutter Cancer Institute, New York University, New York, NY, USA.
M R PhilipsDepartments of Medicine, Cell Biology and Pharmacology, Perlmutter Cancer Institute, New York University, New York, NY, USA.
G EmeryInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.
S MelocheInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada.

Funding

Regulation of K-Ras by a Farnesyl-electrostatic SwitchR01CA116034 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 2005 to 2017
$3.4M
NCI NIH HHS R01 CA116034
6 · The paper itself

Abstract

The Ras-related (R-Ras) isoforms TC21, R-Ras and M-Ras are members of the Ras superfamily of small GTPases. R-Ras family proteins are frequently overexpressed in human cancers, and expression of activated mutants of these GTPases is sufficient to induce cell transformation. Unlike Ras, few activating mutations of R-Ras proteins have been reported in human cancer, and very little is known about the regulation of their activity. In this study, we report that TC21 and R-Ras are phosphorylated on a conserved serine, Ser186 and Ser201, respectively, in intact cells. This residue is located in the C-terminal hypervariable region of the proteins and is not conserved in M-Ras. We show that the MAP kinases ERK1/2 phosphorylate TC21 and R-Ras on this C-terminal serine residue both in vitro and in vivo. Phosphorylation of R-Ras proteins does not affect their subcellular localization or stability but rather stimulates their activation. Phosphorylation-defective mutants of R-Ras and TC21 are compromised in their ability to promote cancer cell adhesion and migration/invasion, respectively. Importantly, we show that phosphorylation of TC21 and R-Ras potentiates their tumorigenic activity in immunodeficient mice. Our results identify a novel regulatory mechanism of the small GTPases TC21 and R-Ras that controls their oncogenic potential.

Indexed as

Amino Acid SequenceCell Transformation, NeoplasticHumansIntracellular SpaceMembrane ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Monomeric GTP-Binding ProteinsPhosphorylationProtein BindingProtein Interaction Domains and MotifsProtein Kinase InhibitorsProtein TransportMembrane ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Monomeric GTP-Binding ProteinsProtein Kinase InhibitorsRRAS2 protein, human

Identifiers

PMID27086924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.